Development of pauci-immune necrotizing glomerulonephritis during pembrolizumab treatment

Clin Exp Nephrol. 2024 Feb;28(2):177-178. doi: 10.1007/s10157-023-02418-x. Epub 2023 Oct 17.

Authors

Jun Matsumoto¹, Yosuke Saka², Tomohiko Naruse²

Affiliations

¹ Department of Nephrology, Kasugai Municipal Hospital, Takakicho 1-1-1, Kasugai City, Aichi Prefecture, 486-8510, Japan. jmatsumoto16@aol.jp.
² Department of Nephrology, Kasugai Municipal Hospital, Takakicho 1-1-1, Kasugai City, Aichi Prefecture, 486-8510, Japan.

PMID: 37847435
DOI: 10.1007/s10157-023-02418-x

No abstract available

Keywords: Immune checkpoint inhibitor; Pauci-immune necrotizing glomerulonephritis; Pembrolizumab.

Publication types

Letter

MeSH terms

Antibodies, Antineutrophil Cytoplasmic
Antibodies, Monoclonal, Humanized / adverse effects
Glomerulonephritis* / chemically induced
Glomerulonephritis* / drug therapy
Humans

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized
Antibodies, Antineutrophil Cytoplasmic